Diabetes

The FDA has approved semaglutide (Ozempic, Novo Nordisk) for the reduction of major adverse cardiovascular (CV) events in patients with type 2 diabetes and established CV disease.

Shingles vaccination recommended by CDC and ADCES.

Eli Lilly added additional affordability options for patients with diabetes who use certain insulin products.

Patients with diabetes now have access to more technology than ever before to help them manage the chronic disease, but the devices can be complicated for patients to use.

Prediabetes can increase the risk the risk of developing type 2 diabetes.

Insulin aspart injection (Fiasp, Novo Nordisk) has been approved for use as a new mealtime insulin option for children with diabetes.

Due to ongoing insulin affordability challenges, Novo Nordisk is offering new cost assistance options for patients with diabetes.

A new study examined diabetes as an independent predictor of heart failure. 

Patients with diabetes are at risk for complications from vaccine-preventable diseases, making immunization especially critical.

As 2019 draws to a close, let’s look back at some of the top pharmacy news stories of the year.

A set of performance measures for older adults with type 2 diabetes at greater risk for hypoglycemia published by the Endocrine Society and Avalere Health.

Based upon results from a military population study presented at ASHP 2019.

Results at ASHP 2019 suggest potential for administration errors without proper guidance.

Results from a poster at ASHP 2019.

Patients with type 2 diabetes should keep taking their medication.

Pharmacist-led initiatives, such as medication therapy management, for chronic diseases can significantly improve patient outcomes.

Great patient care and new business opportunities don’t have to be mutually exclusive.

Previously approved for IV infusion.

Reduces risk for heart failure and cardiovascular disease hospitalizations.

Tips for identifying patients with diabetes who need more direction and help.

Noteworthy diabetes management products and updates making waves this year.

New CGM eliminates fingersticks, introduces new data presentation.

Now approved for risk reductions in patients with type 2 diabetes mellitus.

Now approved in 7mg and 14 mg tablets.

Cost, education, self-monitoring, and more. 

First non-insulin drug for pediatric use approved in nearly 20 years.

Type 2 diabetes mellitus is a risk factor for incident heart failure, according to a new scientific statement from the American Heart Association (AHA), and it increases the risk of morbidity and mortality in patients with established disease.

Originally approved in 2011, aflibercept is a vascular endothelial growth factor (VEGF) inhibitor.

How pipeline promises-and disappointments-are impacting patients with diabetes.